ARTHUR-D.-LITTLE
4.3.2021 09:02:09 CET | Business Wire | Press release
Arthur D. Little (ADL) today released a major telecoms report that identifies key strategies to unlock the value of network assets, diversify product offerings, and succeed in a 5G world. Entitled “Time to accelerate growth” and based on a global survey of over 100 C-level executives, it looks at the ways in which telcos can meet the challenge of soaring data-traffic demands while moving beyond traditional connectivity and legacy services.
The report identifies three main areas that telcos should concentrate on going forward:
- Maximizing 5G’s potential. To further enhance customer experience for B2C, telcos and media companies need to form alliances and use 5G as a means to create new and compelling products for consumers – for example, premium bundles that combine content, experience and devices in novel and exciting ways. To provide solutions to B2B customers beyond connectivity, mobile private networks (MPNs) and network slicing offer key opportunities for 5G monetization. To capture wholesale infrastructure business opportunities, telcos should also consider structural separation into ComCos and NetCos.
- Moving beyond core services. Telcos have attempted to diversify their offerings for decades, often without any significant ROI. Looking at various “beyond core” options, the report identifies how to diversify successfully and recommends four main priorities – target a market which offers both sizable growth and revenues; build a multi-model approach that combines both internal and external resources; work with a “start-up” mind-set and in private equity mode; and adopt a phased and agile approach for roll-out that sequentially prioritizes key concepts.
- Reconfiguring telco assets. Maximizing 5G’s potential in the core businesses of B2C and B2B, kick-starting new wholesale infrastructure businesses, and moving beyond core imply an appropriate reconfiguration of underlying assets and ownership structure. While asset reconfiguration is not new, there is a growing tranche of opportunities that telcos should consider – for example, the TowerCo model promises further options for monetization. Asset reconfiguration can drive value creation by lifting financing constraints, increasing asset utilization, de-risking investment, strengthening the wholesale value proposition, increasing management focus on distinct core businesses, and preempting unfavorable regulatory decisions.
Karim Taga, Managing Partner in ADL’s TIME (Telecommunications, Information Technology, Media & Electronics) Practice , comments: “The ‘scissor effect’ of a widening gap between revenue and investment means that the pressure on telcos’ cash flow has never been so intense. Executives must deliver growth while juggling both increasing capex and investors’ unwillingness to cut back dividends. And the COVID-19 pandemic has certainly not helped matters.
“However, the telecoms industry still has a very bright future ahead if it is willing to embrace the opportunities that exist and move beyond its traditional comfort zone. We hope that this latest edition of our flagship report provides both inspiration and guidance for executives currently strategizing ways to move their company forward.”
The report is available for download here: www.adlittle.com/TimeToAccelerateGrowth
View source version on businesswire.com: https://www.businesswire.com/news/home/20210304005022/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Following Oral Presentation of Phase I Data at AACR 2026, Debiopharm Announces FDA Fast Track Designation for Lunresertib in Combination With Zedoresertib for Genomic-Defined Platinum-Resistant Ovarian Cancer20.4.2026 14:30:00 CEST | Press release
Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard of care to cure cancer and infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the combination of its PKMYT1 inhibitor, lunresertib (Debio2513), and its WEE1 inhibitor, zedoresertib (Debio 0123). The designation is for the treatment of adult patients with CCNE1 amplified, or a deleterious mutation in either FBXW7 or PPP2R1A, platinum-resistant/refractory ovarian cancer. The FDA’s Fast Track program is designed to facilitate the development and expedite the review of new drugs intended to treat serious conditions and fill an unmet medical need. Programs granted Fast Track designation benefit from more frequent communication with the FDA and, if relevant criteria are met, may be eligible for Priority Review and Accelerated Approval of a New Drug Application (NDA). Momentum Following AACR O
Data4Industry-X Empowers Industrial Organizations in Meeting Digital Product Passport Requirements20.4.2026 14:17:00 CEST | Press release
Contributing to the International Manufacturing-X Council Showcase at Hannover Messe, to improve resilience, productivity and innovation in Manufacturing Hannover Messe - Data4Industry-X, the trusted industry data space solution, builds its momentum by accelerating Digital Product Passport (DPP) compliance with trusted, secure and traceable data exchange at scale, as demonstrated at Hannover Messe April 20-24, 2026 . As theDigital Product Passport becomes a regulatory reality for manufacturing organizations, the ability to exchange data in a trusted, secure and traceable environment across the entire supply chain, in compliance with data regulations such as the Data Act, has become critical. Actively contributing to the International Manufacturing-X Council showcase, driven by LNI 4.0 association involving 16 countries, Data4Industry-X, a decentralized environment, demonstrates the use case of the DPP on the battery’s State of Health, and how the battery current capacity and performanc
Ushio Industry & Entertainment Appoints Takuya Matsumoto as President & CEO and Outlines Strategic Direction for the Next Phase20.4.2026 12:32:00 CEST | Press release
Ushio Industry & Entertainment (Ushio INE GmbH) announces the appointment of Takuya Matsumoto as President and Chief Executive Officer, marking a key milestone in the evolution of the business and its integration within the Ushio Group. With more than 20 years of experience across sales, new business development, and global operations, Takuya Matsumoto brings deep industry expertise and a strong leadership track record within Ushio. Most recently, he served as General Manager of the Global Business Unit, where he played a pivotal role in advancing global growth initiatives. A Clear Vision: A strong heritage with a forward-looking vision focused on innovation, operational excellence, and customer value Under Takuya Matsumoto’s leadership, Ushio INE will continue to build on its strong legacy while advancing its mission to deliver high-performance, high-quality lighting solutions across industrial and entertainment markets worldwide. “Our mission is to continuously deliver essential ligh
Compass Pathways to Participate in Needham Virtual Psychedelics Forum on April 27, 202620.4.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that CEO Kabir Nath will participate in a panel entitled “Clinical Risk, Regulatory Reality and the Path to Scale” at the Needham Virtual Psychedelics Forum on April 27, 2026, at 11am-12pm ET. A live audio webcast of this event will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable response
PPG invests in testing line for radiation-curable coatings at Marly, France20.4.2026 11:00:00 CEST | Press release
Installation helps accelerate development cycles, reduce number of customer trials PPG (NYSE: PPG) today announced the installation of an advanced testing line for radiation-curable coatings at its R&D Center of Excellence in Marly, France. The line can test multiple curing technologies, including infrared (IR), ultraviolet (LED, excimer and arc lamps), and electron beam (EB). This investment allows the company to accurately replicate customer production conditions, helping accelerate development cycles and reduce the number of customer trials. Unlike conventional thermal curing, radiation curing requires less energy because it operates at or near ambient temperature. This reduction in energy demand can significantly lower carbon emissions by 65%*, with further gains possible when powered by renewable energy sources. In addition, UV- and EB-curable systems typically use 100% solids formulations with no solvents, reducing or eliminating volatile organic compound emissions. Beyond sustai
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
